文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

替莫唑胺联合左乙拉西坦治疗胶质母细胞瘤术后患者的疗效:一项双盲随机对照试验的研究方案

The efficacy of temozolomide combined with levetiracetam for glioblastoma (GBM) after surgery: a study protocol for a double-blinded and randomized controlled trial.
PubMed 文献 · Trials · 2022-03-28

该研究为单中心双盲随机对照试验,计划招募142例胶质母细胞瘤术后患者,按1:1随机分为试验组(左乙拉西坦联合替莫唑胺化疗34周)与对照组(安慰剂联合替莫唑胺化疗34周),均在接受放疗基础上干预,干预后随访3年,主要结局为无进展生存期,次要结局包括总生存期、卡氏功能状态评分、客观缓解率及不良事件发生率。

要点

  • 胶质母细胞瘤术后标准替莫唑胺化疗的获益受侵袭性生长和耐药限制。
  • 基础实验和回顾性研究提示左乙拉西坦可能提高胶质母细胞瘤患者生存率。
  • 该双盲随机对照试验旨在比较左乙拉西坦联合替莫唑胺与标准替莫唑胺化疗的疗效。

核心结论

  • 该试验预期结果将为左乙拉西坦联合替莫唑胺治疗胶质母细胞瘤的临床获益提供高级别证据。

研究设计与样本

  • 单中心、双盲、随机对照试验,计划招募142例胶质母细胞瘤术后患者。
  • 合格参与者按1:1比例随机分配至试验组或对照组。
  • 两组均在放疗基础上干预:试验组接受左乙拉西坦联合替莫唑胺化疗34周,对照组接受安慰剂片联合替莫唑胺化疗34周。
  • 干预后对所有患者随访3年。

关键数值与推荐

  • 主要结局为无进展生存期(PFS)。
  • 次要结局包括总生存期(OS)、卡氏功能状态评分(KPS)、客观缓解率(ORR)及不良事件发生率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Temozolomide is applied as the standard chemotherapy agent in patients with glioblastoma (GBM) after surgery. However, the benefit of this treatment for patients is limited by the invasive growth of gliomas and drug resistance. There are indications from fundamental experimental and retrospective studies that levetiracetam has the potential to improve the survival rate of patients with GBM. However, it has yet to be determined whether the combination of temozolomide and levetiracetam is more effective than standard temozolomide chemotherapy. Therefore, we designed a randomized clinical trial to investigate the therapeutic effect of the new combined regime for treating GBM. METHODS/DESIGN: This is a double-blind and randomized clinical trial conducted in a single center. One hundred forty-two patients will be recruited and screened for the inclusion and exclusion criteria. Then, eligible participants will be randomly assigned to an experimental group or a control group in a 1:1 ratio. Based on the administration of radiation therapy (RT), participants in the experimental group will be prescribed levetiracetam plus temozolomide chemotherapy for 34 weeks while participants in the control group will receive placebo tablets plus temozolomide for the same duration. A 3-year follow-up will be conducted on all patients after intervention. Accordingly, the primary outcome will be progression-free survival (PFS). The secondary endpoints include overall survival (OS), the Karnofsky Performance Status (KPS), the objective response rate (ORR), and adverse event incidence. DISCUSSION: It is expected that the results of this trial will provide high-level evidence regarding the clinical benefits of levetiracetam and temozolomide combined in the treatment of GBM. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2100049941 . Registered on 14 August 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sun M, Huang N, Tao Y, et al. The efficacy of temozolomide combined with levetiracetam for glioblastoma (GBM) after surgery: a study protocol for a double-blinded and randomized controlled trial. Trials. 2022. PMID: 35346332. doi:10.1186/s13063-022-06168-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。